288 320
[14]
Rodrı´guez-Covarrubias F, Gonza´lez-Ramı´rez A, Aguilar-Davidov B, Castillejos-Molina R, Sotomayor M, Feria-Bernal G. Extended sam- pling at first biopsy improves cancer detection rate: results of a prospective, randomized trial comparing 12 versus 18-core pros- tate biopsy. J Urol 2011;185:2132–6.
[15]
De Matteis A, Bollito E, Galosi AB, et al. Prostate biopsy: character- istics of the histological sample. Arch Ital Urol Androl 2005;77: 28–32.
[16]
Moore CM, Kasivisvanathan V, Eggener S, et al. START Consortium. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 2013;64:544–52.
[17]
Ahmed HU, Hu Y, Carter T, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011;186:458–64.[18]
Kryvenko ON, Carter HB, Trock BJ, Epstein JI. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology 2014;83:869–74.
[19]
Vickers AJ, Sjoberg DD. Guidelines for reporting of statistics in European Urology. Eur Urol 2015;67:181–7.[20]
Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6: 197–206.
[21]
Park BK, Park JW, Park SY, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol 2011;197:W87681.
[22]
Panebianco V, Barchetti F, Sciarra A, et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol 2015; 33:17.e1-7.
[23]
Manfredi M, Costa Moretti T, Emberton M, Villers A, Valerio M. MRI/ US fusion software-based targeted biopsy: the new standard of care? Minerva Urol Nefrol 2015;67:233–46.
[24]
Mozer P, Roupret M, Le Cossec C, et al. First round of targeted biopsies with magnetic resonance imaging/ultrasound fusion images compared to conventional ultrasound-guided transrectal biopsies for the diagnosis of localised prostate cancer. BJU Int 2015;115:50–7.
[25]
Delongchamps NB, Peyromaure M, Schull A, et al. Prebiopsy mag- netic resonance imaging and prostate cancer detection: compari- son of random and targeted biopsies. J Urol 2013;189:493–9.
[26]
Mendhiratta N, Rosenkrantz AB, Meng X, et al. Magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in a consecu- tive cohort of men with no previous biopsy: reduction of over detection through improved risk stratification. J Urol 2015;194: 1601–6.
[27]
Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by trans- rectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without pre- vious prostate biopsies. Eur Urol 2014;66:22–9.
[28]
Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided bi- opsy for the diagnosis of prostate cancer. JAMA 2015;313:390–7.
[29]
Valerio M, Donaldson I, Emberton M, et al. Detection of clinically significant prostate cancer using magnetic resonance imaging– ultrasound fusion targeted biopsy: a systematic review. Eur Urol 2015;68:8–19.
[30]
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imag- ing–Reporting and Data System: 2015, version 2. Eur Urol 2016;69:16–40.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 8 2 – 2 8 8
288